2012
DOI: 10.1590/s1020-49892012001400009
|View full text |Cite
|
Sign up to set email alerts
|

Feasibility study of a smoking cessation intervention in Directly Observed Therapy Short-Course tuberculosis treatment clinics in Rio de Janeiro, Brazil

Abstract: A pilot feasibility study was conducted to determine whether Directly Observed Therapy Short-Course (DOTS) workers could be trained to deliver smoking cessation counseling and referral interventions, identify potential barriers to a full-scale randomized controlled trial on the effectiveness of integrated smoking cessation in DOTS, and determine whether tuberculosis (TB) patients who smoke would agree to participate in such a program. DOTS providers in two Rio de Janeiro primary health clinics received 1-day t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
20
0
5

Year Published

2013
2013
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 25 publications
(28 citation statements)
references
References 12 publications
3
20
0
5
Order By: Relevance
“…Benefits of quitting smoking and quit strategies in patients with TB Training TB healthcare workers using DOTS (directly observed treatment, short-course) in Rio de Janeiro, Brazil to deliver smoking cessation for 1 day improved their self-rated efficacy but the effects on smoking rates were not reported [147].…”
Section: Smoking Cessation In Patients With Tbmentioning
confidence: 99%
“…Benefits of quitting smoking and quit strategies in patients with TB Training TB healthcare workers using DOTS (directly observed treatment, short-course) in Rio de Janeiro, Brazil to deliver smoking cessation for 1 day improved their self-rated efficacy but the effects on smoking rates were not reported [147].…”
Section: Smoking Cessation In Patients With Tbmentioning
confidence: 99%
“…[65][66][67] In SA, with the added risk of HIV, the importance of smoking cessation to reduce the risk of TB, HIV-related diseases and COPD is unquestionable. [6,68] There are some data to show that integrating smoking cessation efforts (support plus NRT) with TB treatment is feasible, [69] improves quit rates (77% v. 8.7%, respectively) and completion of TB treatment (97.5% v. 84.8%, respectively). [70] It is unclear, however, whether stopping smoking during TB therapy will reduce the excess mortality associated with smoking and TB, [71] nor are there any efficacy data available on whether using bupropion or varenicline with concomitant anti-TB therapy may be of benefit.…”
Section: Tuberculosismentioning
confidence: 99%
“…This scenario may be result from the fragile interaction between researchers and TB and HIV managers, who prioritize activities in TB, TB/HIV care, or surveillance activities, but not research. In addition, favorable results obtained through research carried out in high burden countries, such as Brazil, usually do not have long-term sustainability and are not incorporated into the routine of the health system [21][22][23][24] . Among the most widely used interventions recommended by the WHO, we cite the adoption of an early diagnosis of drug-resistant and drug-sensitive TB using new technologies (usually molecular tests) aiming to adopt appropriate treatment and taking measures to control TB infection in the community [25][26] .…”
mentioning
confidence: 99%